Skip to content
Subscriber Only

AstraZeneca’s Diabetes Drug May Raise Death Risk, FDA Says

Updated on

AstraZeneca Plc’s type 2 diabetes drug Onglyza showed an increased risk of death in an analysis by U.S. regulators of a clinical trial on the heart effects of the treatment.

Food and Drug Administration staff said their analysis of deaths in the trial suggested patients using Onglyza experienced “significant or near-significant” increases in death from all causes, not just heart problems.